Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
According to a Bloomberg report, two private equity firms, In October 2023, Sanofi SA (NASDAQ:SNY) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development pipeline and cut costs.
2023年10月，赛诺菲安万特公司（纳斯达克:SNY）宣布计划将其消费者保健业务拆分，法国药品公司概述了其战略更新，以增加投资于药物开发管线并削减成本。
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
赛诺菲表示，这一分拆将使其能够更加专注于创新药物和疫苗。
Sanofi's consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.
赛诺菲的消费者健康部门拥有包括Phytoxil止咳糖浆、Icy Hot止痛凝胶和Dulcolax泻药片在内的热门非处方产品组合。
According to a Bloomberg report, two private equity firms, Clayton Dubilier & Rice and PAI Partners, made separate bids for Sanofi's consumer health division.
根据彭博社的一份报告，两家股权投资公司Clayton Dubilier & Rice和PAI Partners分别对赛诺菲的消费者健康部门进行了独立竞标。
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
该更新将使这家欧洲制药巨头更接近今年欧洲最大交易之一，这笔交易可能使该部门的估值达到150亿欧元（168亿美元）或更高，报道补充道。
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
预计分拆将于2024年第四季度发生，通过创建总部位于法国的上市实体。
In July, Goldman Sachs Group Inc. (NYSE:GS) and Morgan Stanley (NYSE:MS) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring Sanofi's consumer health division.
7月，高盛集团（纽约证交所:GS）和摩根士丹利（纽约证交所:MS）表示他们正准备为有意收购赛诺菲消费者健康部门的潜在买家安排超过650亿美元（600亿欧元）的债务融资。
The move highlighted banks' interest in supporting leveraged buyouts through pre-arranged financing.
此举突显了银行对通过预先安排融资支持杠杆收购的兴趣。
Sanofi may opt for a spinoff of its consumer health business if the offers aren't appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
如果报价不理想，赛诺菲可能选择剥离其消费业务，彭博社援引消息人士称。该公司发言人告诉彭博社，赛诺菲正在评估潜在的分离选择，最早可能在今年第四季度发生交易，并指出准备工作正在按计划进行。
In November 2023, Sanofi reportedly initiated talks with Rothschild & Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business at over $20 billion.
据悉，赛诺菲于2023年11月与Rothschild & Co.展开谈判，探讨将其消费保健部门剥离的可能性，这可能使该业务的价值超过200亿美元。
Rival pharma giants GSK Plc (NYSE:GSK) and Johnson & Johnson (NYSE:JNJ) split their consumer healthcare units Haleon Plc (NYSE:HLN) and Kenvue Inc (NYSE:KVUE), respectively.
竞争对手制药巨头葛兰素Smith克莱恩公司（纽交所：GSK）和强生公司（纽交所：JNJ）分拆了其消费保健部门，分别为海伦公司（纽交所：HLN）和肯维公司（纽交所：KVUE）。
Price Action: SNY stock closed at $57.62 on Tuesday.
股价走势：赛诺菲股票周二收盘价为57.62美元。
